论文信息 - Phase I pharmacokinetic study of DUP-937, a new anthrapyrazole - 字舞流文

Phase I pharmacokinetic study of DUP-937, a new anthrapyrazole

K. Bélanger | E. Eisenhauer | L. Whitfield | J. Maroun | D. Stewart | J. Jolivet | N. Wainman | A. Grillo‐López

[1] C. Erlichman,et al. Phase I pharmacokinetic and pharmacodynamic study of a new anthrapyrazole, CI-937 (DUP937). , 1991, Cancer research.

[2] C. Loprinzi,et al. Phase I and clinical pharmacological evaluation of pirozantrone hydrochloride (oxantrazole). , 1990, Cancer research.

[3] L. Grochow,et al. Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole. , 1990, Cancer research.

[4] H. Showalter,et al. Development of a radioimmunoassay for the anthrapyrazole chemotherapy agent CI-937 and the pharmacokinetics of CI-937 in rats. , 1989, Cancer research.

[5] Newell,et al. PHASE-I STUDY OF THE ANTHRAPYRAZOLE CI-941 WITH PHARMACOKINETICALLY GUIDED DOSE ESCALATION , 1988 .

[6] H. D. Showalter,et al. Anthrapyrazole anticancer agents. Synthesis and structure-activity relationships against murine leukemias. , 1987, Journal of medicinal chemistry.

[7] R. Novak,et al. Effects of anthrapyrazole antineoplastic agents on lipid peroxidation. , 1986, Biochemical and biophysical research communications.

[8] D. W. Fry,et al. Design, biochemical pharmacology, electrochemistry and tumour biology of anti-tumour anthrapyrazoles. , 1986, Anti-cancer drug design.

[9] W. Leopold,et al. Anthrapyrazoles, a new class of intercalating agents with high-level, broad spectrum activity against murine tumors. , 1985, Cancer research.